Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) shares traded up 5.4% during mid-day trading on Wednesday . The stock traded as high as $1.83 and last traded at $1.85. 459,894 shares were traded during mid-day trading, a decline of 76% from the average session volume of 1,943,259 shares. The stock had previously closed at $1.75.
Analyst Ratings Changes
Several research firms have recently weighed in on NUVB. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Wedbush reaffirmed an "outperform" rating and set a $5.00 price target on shares of Nuvation Bio in a research note on Thursday, March 27th. HC Wainwright cut their price objective on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, Jones Trading assumed coverage on shares of Nuvation Bio in a research report on Wednesday, March 12th. They issued a "buy" rating and a $10.00 target price for the company.
Read Our Latest Report on Nuvation Bio
Nuvation Bio Price Performance
The company's 50-day simple moving average is $2.10 and its 200-day simple moving average is $2.43. The stock has a market capitalization of $611.32 million, a P/E ratio of -0.83 and a beta of 1.47.
Hedge Funds Weigh In On Nuvation Bio
A number of institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC bought a new position in shares of Nuvation Bio during the 4th quarter worth approximately $27,000. Forum Financial Management LP bought a new position in Nuvation Bio during the fourth quarter worth $29,000. Cerity Partners LLC acquired a new position in shares of Nuvation Bio in the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its position in shares of Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after purchasing an additional 15,791 shares during the period. Finally, Abacus Planning Group Inc. acquired a new stake in shares of Nuvation Bio during the 4th quarter worth about $44,000. Institutional investors and hedge funds own 61.67% of the company's stock.
About Nuvation Bio
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Recommended Stories
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
